Want to see IN:SUPRIYA full AI Analyst Report?
SUPRIYA Stock Chart & Stats
₹751.00
-₹18.10(-2.41%)
At close: 4:00 PM EST
₹751.00
-₹18.10(-2.41%)
Day’s Range― - ―
52-Week Range₹545.65 - ₹1,085.50
Previous CloseN/A
Volume168.68K
Average Volume (3M)18.01K
Market Cap
₹78.84B
Enterprise Value₹72.86B
Total Cash (Recent Filing)₹788.67M
Total Debt (Recent Filing)₹54.35M
Price to Earnings (P/E)38.3
Beta1.24
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.13%
Share Statistics
EPS (TTM)25.98
Shares Outstanding80,482,800
10 Day Avg. Volume18,341
30 Day Avg. Volume18,009
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)3.78
Price to Sales (P/S)5.46
P/FCF Ratio105.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)30.5
Revenue Forecast (FY)₹9.94B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet (low Leverage)Very low leverage and expanding equity provide durable financial flexibility. This reduces default and refinancing risk, supports continued capital investment in API capacity, and allows Supriya to pursue longer-term contracts or scale production without relying on external debt markets.
Sustained Multi-year Revenue GrowthConsistent multi-year top-line expansion signals lasting demand for the company’s API portfolio across therapeutic areas and geographies. Durable revenue growth supports capacity utilization, long-term customer relationships, and incremental operating leverage as scale increases.
Improving Operating Cash Flow And FCF ReboundA sustained improvement in operating cash flow and a recent free cash flow rebound enhance internal funding capacity for capex, R&D and working capital. This strengthens self-financing ability and lowers reliance on external financing for medium-term growth initiatives.
Bears Say
Volatile Margins And EarningsEarnings and margin variability point to exposure to product-mix shifts, raw-material costs, and pricing cycles in the API market. This structural volatility can complicate forecasting, capital allocation and long-term return targets even as revenues grow.
History Of Inconsistent Free Cash FlowPast negative FCF through multiple years reflects heavy capex or working-capital demands tied to scale-ups. If cash generation reverts, the company may need external funding or delay investments, constraining strategic initiatives and shareholder returns over the medium term.
Returns Normalizing From Earlier HighsAs Supriya scales and equity base grows, historically high ROE has moderated. Sustaining high returns will require continued margin control, productivity gains, and successful deployment of incremental capital—any shortfall could pressure long-term shareholder returns.
Supriya Lifescience Limited News
SUPRIYA FAQ
What was Supriya Lifescience Limited’s price range in the past 12 months?
Supriya Lifescience Limited lowest stock price was ₹545.65 and its highest was ₹1085.50 in the past 12 months.
What is Supriya Lifescience Limited’s market cap?
Supriya Lifescience Limited’s market cap is ₹78.84B.
When is Supriya Lifescience Limited’s upcoming earnings report date?
Supriya Lifescience Limited’s upcoming earnings report date is Aug 10, 2026 which is in 37 days.
How were Supriya Lifescience Limited’s earnings last quarter?
Supriya Lifescience Limited released its earnings results on May 27, 2026. The company reported ₹9.2 earnings per share for the quarter, beating the consensus estimate of N/A by ₹9.2.
Is Supriya Lifescience Limited overvalued?
According to Wall Street analysts Supriya Lifescience Limited’s price is currently Overvalued.
Does Supriya Lifescience Limited pay dividends?
Supriya Lifescience Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.13%. See more information on Supriya Lifescience Limited dividends here
What is Supriya Lifescience Limited’s EPS estimate?
Supriya Lifescience Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Supriya Lifescience Limited have?
Supriya Lifescience Limited has 80,482,800 shares outstanding.
What happened to Supriya Lifescience Limited’s price movement after its last earnings report?
Supriya Lifescience Limited reported an EPS of ₹9.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.5%.
Which hedge fund is a major shareholder of Supriya Lifescience Limited?
Currently, no hedge funds are holding shares in IN:SUPRIYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Technical Analysis
Blue Jet Healthcare Limited
―
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
Zota Health Care Ltd.
―
OneSource Specialty Pharma Limited
―